title: Stabilization of atherosclerotic plaques: an update.
authors: A.I. Virtanen Institute, University of Eastern Finland, FI-70211 Kuopio, Finland.
authors: Seppo
authors: S
authors: Ylä-Herttuala
authors: Jacob Fog
authors: JF
authors: Bentzon
authors: Mat
authors: M
authors: Daemen
authors: Erling
authors: E
authors: Falk
authors: Hector M
authors: HM
authors: Garcia-Garcia
authors: Joerg
authors: J
authors: Herrmann
authors: Imo
authors: I
authors: Hoefer
authors: Suvi
authors: S
authors: Jauhiainen
authors: J Wouter
authors: JW
authors: Jukema
authors: Rob
authors: R
authors: Krams
authors: Brenda R
authors: BR
authors: Kwak
authors: Nikolaus
authors: N
authors: Marx
authors: Marek
authors: M
authors: Naruszewicz
authors: Andrew
authors: A
authors: Newby
authors: Gerard
authors: G
authors: Pasterkamp
authors: Patrick W J C
authors: PW
authors: Serruys
authors: Johannes
authors: J
authors: Waltenberger
authors: Christian
authors: C
authors: Weber
authors: Lale
authors: L
authors: Tokgözoglu
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D053299:Apolipoprotein B-100 / Q000037:antagonists & inhibitors; D001792:Blood Platelets / Q000502:physiology; D065100:CCR5 Receptor Antagonists; D018946:Chemokine CCL5 / Q000037:antagonists & inhibitors; D008076:Cholesterol, HDL / Q000187:drug effects; D003324:Coronary Artery Disease / Q000473:pathology / Q000517:prevention & control; D016207:Cytokines / Q000378:metabolism; D003952:Diagnostic Imaging; D004730:Endothelium, Vascular / Q000502:physiology; D005820:Genetic Testing; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D007962:Leukocytes / Q000473:pathology; D018919:Neovascularization, Physiologic / Q000502:physiology; D009525:Niacin / Q000627:therapeutic use; D010447:Peptide Hydrolases / Q000502:physiology; D010740:Phospholipases / Q000037:antagonists & inhibitors; D058226:Plaque, Atherosclerotic / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors; D019713:Receptors, CCR5; D012697:Serine Endopeptidases; D012907:Smoking / Q000009:adverse effects; D013234:Stem Cells / Q000502:physiology; D013312:Stress, Physiological / Q000502:physiology
chemical_list: D000959:Antihypertensive Agents; D053299:Apolipoprotein B-100; C483024:CCL5 protein, human; D065100:CCR5 Receptor Antagonists; C584933:CCR5 protein, human; D018946:Chemokine CCL5; D008076:Cholesterol, HDL; D016207:Cytokines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D036341:Intercellular Signaling Peptides and Proteins; D010975:Platelet Aggregation Inhibitors; D019713:Receptors, CCR5; D009525:Niacin; D010740:Phospholipases; D010447:Peptide Hydrolases; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases